» Articles » PMID: 33117611

Ocular Surface Potential Difference Measured in Human Subjects to Study Ocular Surface Ion Transport

Overview
Date 2020 Oct 29
PMID 33117611
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The epithelium lining the ocular surface, which includes corneal and conjunctival epithelia, expresses the prosecretory chloride channel cystic fibrosis transmembrane conductance regulator (CFTR) and the proabsorptive epithelial sodium channel (ENaC). Here, methodology was established to measure the millivolt (mV) potential differences at the ocular surface, called ocular surface potential difference (OSPD), in human subjects produced by ion transport.

Methods: OSPD was measured in human subjects in which a fluid-filled measuring electrode contacted a fluid pool created by eversion of the lateral lower eyelid, with a reference electrode placed subcutaneously in the forearm. Through the use of a high-impedance voltmeter, OSPD was measured continuously over 10 to 15 minutes in response to a series of perfusate fluid exchanges.

Results: Baseline OSPD (± SEM) in six normal human subjects was -21.3 ± 3.6 mV. OSPD depolarized by 1.7 ± 0.6 mV following the addition of the ENaC inhibitor amiloride, hyperpolarized by 6.8 ± 1.5 mV with a zero chloride solution, and further hyperpolarized by 15.9 ± 1.6 mV following CFTR activation by isoproterenol. The isoproterenol-induced hyperpolarization was absent in two cystic fibrosis subjects lacking functional CFTR. OSPD measurement produced minimal epithelial injury.

Conclusions: Our results establish the feasibility and safety of OSPD measurement in humans and demonstrate robust CFTR activity, albeit minimal ENaC activity, at the ocular surface. OSPD measurement may be broadly applicable to investigate fluid transport mechanisms and test drug candidates to treat ocular surface disorders.

Translational Relevance: To the best of our knowledge, this is the first measurement of the electrical potential generated by the ocular surface epithelium in human subjects, offering a new approach to study ocular surface function and health.

Citing Articles

Calcium-sensing receptor (CaSR) modulates ocular surface chloride transport and its inhibition promotes ocular surface hydration.

Pasricha N, Lindgren E, Yan R, Kuo Y, Chan M, Verkman A Ocul Surf. 2024; 34:30-37.

PMID: 38871216 PMC: 11887457. DOI: 10.1016/j.jtos.2024.06.002.


Ocular Surface Ion Transport and Dry Eye Disease.

Lindgren E, Cil O, Verkman A, Pasricha N Curr Ophthalmol Rep. 2024; 10(4):188-197.

PMID: 38213468 PMC: 10783585. DOI: 10.1007/s40135-022-00295-3.


Synthetic Strategies for Improving Solubility: Optimization of Novel Pyrazolo[1,5-]pyrimidine CFTR Activator That Ameliorates Dry Eye Disease.

Kim B, Oh C, Jeon D, Jun I, Lee H, Kim B J Med Chem. 2022; 66(1):413-434.

PMID: 36573286 PMC: 9841530. DOI: 10.1021/acs.jmedchem.2c01382.


Differences in vulnerability to desiccating stress between corneal and conjunctival epithelium in rabbit models of short-term ocular surface exposure.

Jeon H, Kang B, Li X, Song J Sci Rep. 2022; 12(1):16941.

PMID: 36209216 PMC: 9547869. DOI: 10.1038/s41598-022-21478-9.


Novel CFTR Activator Cact-3 Ameliorates Ocular Surface Dysfunctions in Scopolamine-Induced Dry Eye Mice.

Jeon D, Jun I, Lee H, Park J, Kim B, Ryu K Int J Mol Sci. 2022; 23(9).

PMID: 35563597 PMC: 9101838. DOI: 10.3390/ijms23095206.


References
1.
Ahrens R, Standaert T, Launspach J, Han S, Teresi M, Aitken M . Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol. 2002; 33(2):142-50. DOI: 10.1002/ppul.10043. View

2.
Jamerson E, Elhusseiny A, ElSheikh R, Eleiwa T, El Sayed Y . Role of Matrix Metalloproteinase 9 in Ocular Surface Disorders. Eye Contact Lens. 2020; 46 Suppl 2:S57-S63. DOI: 10.1097/ICL.0000000000000668. View

3.
Flores A, Casey S, Felix C, Phuan P, Verkman A, Levin M . Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease. FASEB J. 2016; 30(5):1789-97. PMC: 4836376. DOI: 10.1096/fj.201500180. View

4.
Chen X, Lee S, Zhang T, Duan T, Pasricha N, Schallhorn J . Nanomolar Potency Aminophenyltriazine CFTR Activator Reverses Corneal Epithelial Injury in a Mouse Model of Dry Eye. J Ocul Pharmacol Ther. 2020; 36(3):147-153. PMC: 7175624. DOI: 10.1089/jop.2019.0087. View

5.
Rowe S, Liu B, Hill A, Hathorne H, Cohen M, Beamer J . Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One. 2013; 8(7):e66955. PMC: 3724869. DOI: 10.1371/journal.pone.0066955. View